ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

December 06, 2006 10:34 ET

ALDA Retains RAMPartners of Geneva to Raise Funds for Therapeutics

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 6, 2006) - ALDA Pharmaceuticals Corp. (TSX VENTUREAPH) ("ALDA") announces that it has retained Rhone Alternative Marketing Partners ("RAMP") of Geneva, Switzerland to raise funds in Europe to undertake the testing and registration of the topical therapeutic applications of ALDA's T36® technology. Dr. Terrance Owen, President & CEO, states, "We are extremely pleased to be working with such an eminent group as RAMP. We look forward to securing the financing that is required for ALDA to prepare its therapeutic products for the market."

About RAMP

RAMP has extensive experience in raising capital for companies in Europe and North America through its network of institutional investors in the major European financial centres.

About ALDA

ALDA's patent-pending T36® formulation contains active ingredients in very low concentrations that act synergistically to disrupt the physical structure of all micro-organisms rather than interfering with the metabolic pathways. The competitive advantage is a high degree of effectiveness and safety while preventing microbial resistance, side effects or toxicity.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information